![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjVAzqPLkQbKX6hLcD-rvJIxaflpq20GROx6gB8AJF6FqZwb4cCAL2zxSLiqlv5lVJZ36G29OjQPiCCsYAQVIsBdSxtNPEq220eTlmI-we1cOyiZdQSk7-EMCjMi92qyfo2OIpvbPlrtQUv/s640/Hardy.jpg)
培養基 - GBS DetectTM (原廠資訊連結)
臨床應用
Hardy
Diagnostics GBS DetectTM用以次培養經過增菌培養基(如StrepB Carrot BrothTM 及LIM Broth)培養後的懷孕婦女篩檢B群鏈球菌檢體,可誘發不溶血或微弱溶血B群鏈球菌產生β溶血,用以分離及偵測非溶血(γ-hemolytic)的B群鏈球菌。
原理與介紹
早發性新生兒B群鏈球菌感染疾病有極高的致死率。針對懷孕35至37週婦女篩檢培養B群鏈球菌為美國疾病管制局新生兒B群鏈球菌疾病預防指導方針中建議使用的標準方法。方針中建議必須使用Strep B Carrot
Broth™或LIM Broth作檢體的增菌培養以增加分離率。Strep B Carrot
Broth™針對β溶血性的B群鏈球菌可產生肉眼可見的顏色而可直接鑑別GBS的存在,不需另行操作鑑定試驗,可增加β溶血性的B群鏈球菌檢出率,並簡化鑑定流程。但無論使用可產色的Strep B Carrot
Broth™或是傳統的LIM Broth,γ溶血性B群鏈球菌由於在一般的含綿羊血平板培養基生長不會產生溶血,因此不易與其它小型不溶血的菌落區別,容易被錯失挑取,向來為實驗室人員的挑戰之一。
Hardy Diganostics 的GBS DetectTM
平板培養基除添加選擇性配方可抑制大腸桿菌群,葡萄球菌,以及其它一般常在菌的的生長外,另外含有溶血誘導因子,可引發微弱溶血或是不溶血的B群鏈球菌菌株產生強溶血反應。可減少篩檢γ溶血性B群鏈球菌的步驟,同時搭配Strep B Carrot Broth™ 應用可簡化B群鏈球菌篩檢流程,並增加所有B群鏈球菌的分離率。
臨床評估
1.
C- 101 Evaluation of GBS Detect and ChromID Strepto B agars for the
detection of Group B streptococcus from GBS Screening Broth Medium (GBS)
Zarna A. Shah1 , Jessica D. Dolloff1, Sandy Tarleton1, and R. L. Sautter2
1Carolinas Laboratory Network, Charlotte, NC and 2Carolinas
Pathology Group, Charlotte, NC
研究方法: 此研究以GBS DetectTM 與ChromID Strepto B agar分別進行116及112個臨床檢體的試驗。另外以300個檢體進行此二種培養基的平行比較,以包含PCR鑑定的兩法皆為陽性的結果為標準。
結果:應用GBS DetectTM的116個檢體臨床評估檢出率為38.79%,而採用ChromID
Strepto B agar的112個檢體臨床評估檢出率為24.11%。300個平行比較的檢體以標準法判定共分離出B群鏈球菌57株,GBS DetectTM檢出55株,敏感性為96.49%
(55/57),而ChromID
Strepto B agar檢出27株,敏感性47.37%(27/57)
2.
C-135 Evaluation of GBS Detect™: a New Medium for the Detection of
Non-Hemolytic Group B Strep in Subcultures of Carrot Broth™ and LIM Broth. Results
of a Multi-Center Trial
R.
Clasen*1, V. Cuna1, S. Dolan2, J. Bartos3, J. Spoerke4 , G. Peterson5, B.
Peterson6, Mary Colson-Burns6, I. Yeung7, J. Hardy1
1*Hardy
Diagnostics, Santa Maria, California, 2Bethesda Oak Hospital, Cincinnati, Ohio,
3Aurora Health Care, Milwaukee, Wisconsin, 4Columbia -St. Mary’s, Milwaukee,
Wisconsin, 5Central Coast Pathology, San Luis Obispo,
California,
6Allina Laboratories, Abbott-Northwestern Hospital, Minneapolis, Minnesota,
7Kaiser Berkeley Central Laboratory, Berkeley, California.
研究方法: 六家使用LIM Broth或StrepB Carrot Broth為B群鏈球菌增菌培養的醫院,自2007年十一月至2008年4月共收檢619個檢體,檢體經增殖後,次培養於BAP與GBS DetectTM培養基上。懷疑為GBS的菌落以CAMP法或乳膠凝集試驗進行鑑定。
結果: 619個臨床檢體共檢出GBS 107株,在BAP及GBS
DetectTM上皆分離出的GBS共83株(占全部分離出菌株之77.5%[83/107]),僅在GBS DetectTM上分離出的GBS共24株(占全部分離出菌株之22.4%[24/107])。沒有GBS是只在BAP上被分離出來的。
產品圖樣
Reference
1. Illumigene GBS: A Novel New
Molecular Approach for the Detection of Group B Streptococcus, Jodi Wince, ASM
2011, http://m.core-apps.com/TriStar-ASM2011/abstract/84dc19e6de1adf2c66b74fa
54f6cf5d8, accessed 4/9/12
2. Crystal J. Redfern, MT (ASCP); Robert L.
Sautter, PhD, HCLD (ABB), Near-Patient Testing for Group B Streptococci
Screening. Point of Care: T he Journal of Near-Patient Testing &
Technology: Volume 8(1)March 2009 pp 25-28
3. 2010 Guidelines for the Prevention of Perinatal
Group B Streptococcal Disease http://www.cdc.gov/groupbstrep/guidelines/guidelines.html,accessed 4/9/12
4.
EVALUATION OF THE
ILLUMIGENE GBS METHOD, HARDY DETECT AND G BS CHROME AGARS FOR THE DETECTION OF
GROUP B STREPTOCOCCUS FROM GBS BROTH Jessica D. Dolloff1, Zarna A.
Shah1, and R. L. Sautter2 1Carolinas Laboratory Network, Charlotte,
沒有留言:
張貼留言